Fate Therapeutics【FATE】銘柄情報

Fate Therapeutics Inc (FATE) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.97

( -10.86% )

買値

1.96

売値

1.98

出来高

3,886,105

1.94 日の範囲 2.195

0.910001 52 週間の範囲 2.88

時価総額

229.622M

前日終値

2.21

始値

2.15

時刻

348

1.97

(formt)

最終取引時間

財務取引量

US$ 7,864,384

VWAP

2.0237

平均取引量 (3 か月)

US$ 2,472,331

発行済株式数

116,559,186

配当利回り

PER

-2.41

1 株当たり利益 (EPS)

-1.09

歳入

6.32M

純利益

-129.91M

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is i... Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.fatetherapeutics.com

本社

San Diego, United States

設立

2026

Fate Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker FATE. The last closing price for Fate Therapeutics was US$2.21. Over the last year, Fate Therapeutics shares have traded in a share price range of US$ 0.910001 to US$ 2.88.

Fate Therapeutics currently has 116,559,186 shares in issue. The market capitalisation of Fate Therapeutics is US$229.62 million. Fate Therapeutics has a price to earnings ratio (PE ratio) of -2.41.

Form 8-K - Current report

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage...

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026...

Form 4 - Statement of changes in beneficial ownership of securities

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage...

Form 144 - Report of proposed sale of securities

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.71	-26.4925373134	2.68	2.88	1.9522	5336933	2.52239494	CS
4	-0.43	-17.9166666667	2.4	2.88	1.59	4626816	2.27398179	CS
12	0.79	66.9491525424	1.18	2.88	1.04	2879895	1.95883393	CS
26	0.89	82.4074074074	1.08	2.88	0.951	2209091	1.66400192	CS
52	0.56	39.7163120567	1.41	2.88	0.910001	2050782	1.46276421	CS
156	-3.28	-62.4761904762	5.25	8.83	0.66105	2213810	2.78362428	CS
260	-73.71	-97.3969344609	75.68	97.43	0.66105	2024774	10.82368612	CS